ClinicalTrials.gg
CompletedNCT01789242Updated Oct 18, 2017

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

A Phase 1 interventional study of Carfilzomib and Dexamethasone in Amyloidosis and Systemic Light Chain Amyloidosis, sponsored by Criterium, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-18.

Sponsored by Criterium, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.

Enrollment
61st of 99
32 · median 45
Started
2013
with 10 others
Phase 1
12 of 141
3 open now
Registered
31st of 141
by date

Among the 141 studies in Amyloidosis with a site in United States, this one is the 61st largest by enrollment of the 99 interventional ones that give a count, is one of 11 that started in 2013, is one of 12 in phase 1, and was the 31st registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.

Read the detailed description

This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis. The study will also explore the efficacy of carfilzomib in both proteasome inhibitor-naive and proteasome inhibitor-exposed patients including hematologic response, organ response, progression free survival, and time to next therapy.

03

Conditions studied

  • Amyloidosis
  • Systemic Light Chain Amyloidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 18 years of age
  • -proven AL amyloidosis, confirmed by positive Congo red stain with green birefringence on polarized light microscopy with evidence of measurable clonal disease that requires active treatment as defined below:
  • Patients must have clonal disease measureable by serum free light chain (FreeliteTM) assay:

    • For the dose-escalation cohort: this is defined as having any elevation in the amyloidogenic (i.e. clonal) light chain with an abnormal free kappa:lambda ratio
    • For the dose expansion cohorts: in addition to the above, there must be a difference between the amyloidogenic (i.e. clonal) and non-amyloidogenic light chain (dFLC) of at least 50mg/L (5mg/dL)
  • (progressed after prior response) or refractory (failed to achieve at least a partial response) to at least one prior therapy for amyloidosis.

    • Patients that received an stem cell transplant must be at least 3 months post-transplant and recovered from acute transplant-related toxicities.
    • Patients that were unable to tolerate at least 1 cycle of an alkylating agent plus (e.g. melphalan + dexamethasone) or alternative prior regimen because of severe adverse events (e.g. reaction) may be considered after discussion with the study PI/Medical Monitor.
  • Objective, measureable, symptomatic organ involvement, defined as one or more of the following:

    • Kidney: albuminuria ≥ 500 mg/day in a 24-hour urine specimen
    • Heart: presence of mean left ventricular wall thickness on echocardiogram greater than 12 mm in the absence of hypertension or valvular heart disease, or unexplained low voltage (\< 0.5 mV) on , or NT-proBNP > 332 ng/L in the absence of impaired renal function [estimated (eGFR) \< 45 mL/min]
    • Liver: hepatomegaly on physical exam with elevated alkaline phosphatase > 1.5 x
    • GI Tract: showing amyloid deposition along with symptoms such as GI bleeding or persistent diarrhea (> 4 loose stools/day) Autonomic or Peripheral Nervous System: defined as orthostasis, symptoms of nausea or dysgeusia, recurrent diarrhea or constipation, abnormal sensory and/or motor findings on neurologic exam, or gastric atony by gastric emptying scan
    • Note: Skin, lymph node, or soft tissue involvement; carpal tunnel syndrome; or bone marrow amyloid as the sole clinical manifestations of amyloidosis are not sufficient for inclusion.
  • Amyloid cardiac biomarker stage I or II disease Staging defined by NT-proBNP and troponin T cut-offs of \< 332 pg/mL and \<0.035 ng/mL, respectively, as thresholds: Stage I, both under threshold; and Stage II, either troponin or NT-proBNP (but not both) over threshold. If troponin T is not available at local institution, troponin I may be used, but threshold is \<0.1 ng/mL.23
  • (ECOG) Performance Status of 0-2
  • Clinical laboratory values as specified within 14 days of treatment:

    • (ANC) ≥ 1.0 x 109/L
    • ≥8 g/dL [transfusion permitted]
    • count ≥75.0 x 109/L
    • Total ≤ 2 x Upper Limit of Normal (ULN)
    • Alkaline phosphatase ≤ 5 x ULN
    • (ALT) and aspartate aminotransferase (AST) ≤ 3.5 x ULN
    • ≥ 30 mL/min as measured by 24-hour urine
    • Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks
    • Screening platelet count should be independent of platelet transfusions for at least 2 weeks
  • Written in accordance with federal, local, and institutional guidelines
  • Females of must agree to ongoing pregnancy testing and to practice or abstain from heterosexual intercourse
  • Male patients must agree to practice contraception or to abstain from heterosexual intercourse
  • Male patients must agree not to donate semen or sperm
  • of ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Major surgery within 21 days prior to first dose
  • Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
  • Treatment with an experimental drug within 28 days of first dose
  • Active (HIV) or or C infection
  • Bone marrow plasma cells ≥ 30% or clinical manifestations of multiple myeloma, such as hypercalcemia or lytic bone lesions
  • Cardiac exclusions:

    • (LVEF) \< 40%
    • Amyloid cardiac biomarker stage III disease, defined as both NT-proBNP ≥ 332 pg/mL and troponin T ≥ 0.035 ng/mL. If troponin T is not available at local institution, troponin I may be used, but cut-off is ≥ 0.1 ng/mL
    • (NYHA) classification III or IV heart failure (see Appendix G) despite medical management
    • Unstable angina or myocardial infarction within 6 months prior to first dose
    • Grade 2 or 3 atrioventricular (AV) block (Mobitz type I is permitted) or sick sinus syndrome, unless subject has a pacemaker
    • Known history of sustained (> 30 second) ventricular tachycardia or cardiac syncope. Known history of recurrent non-sustained ventricular tachycardia (> 3 beats) despite anti-arrhythmic therapy
    • Supine systolic blood pressure \< 90 mm Hg, or symptomatic orthostatic hypotension, or a decrease in systolic blood pressure upon standing of > 20 mm Hg despite medical management (e.g. midodrine, fludrocortisones)
  • Significant peripheral neuropathy (Grade 3, Grade 4, or Grade 2 with pain) within 14 days prior to first dose
  • Severe diarrhea (≥ grade 3) not controllable with medication or that requires total parenteral nutrition
  • History of bleeding diathesis, known factor X deficiency (level \< 20%), or requirement for therapeutic anticoagulation with warfarin
  • Known allergies to carfilzomib or Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  • Presence of other active with the exception of non-melanoma skin cancer, cervical cancer, treated early-stage prostate cancer provided that prostate-specific antigen is within normal limits, or any completely resected carcinoma in situ
  • Serious psychiatric or medical conditions that could interfere with treatment
  • to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir)
  • Patients in whom the required program of oral and IV fluid hydration is contraindicated, e.g. due to severe pre-existing pulmonary, cardiac, or renal impairment
  • Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to first dose.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Carfilzomib

    All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (\<VGPR after 4 cycles) will have Dexamethasone added to their treatment.

    Drug: Carfilzomib · Drug: Dexamethasone

Interventions

  • IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.

    Also known as: PR-171, Kyprolis

  • Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Adverse Events as a Measure of Safety and Tolerability

    Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment

    Time frame: Throughout treatment, estimated at 8 months per patient

Secondary outcomes

  1. Hematologic Response

    Hematologic Response Rates (PR, VGPR, and CR

    Time frame: Every 28 days while on treatment (estimated at 8 months per patient)

  2. Organ Response

    Organ response rates by standard criteria

    Time frame: Every 112 days while on treatment (estimated at 8 months per patient)

  3. Progression Free Survival

    Time frame: throughout study and follow up (every 2-3 months for 2 years

  4. Time to next therapy

    Time frame: throughout follow up (every 2-3 months for 2 years)

Other outcomes

  1. Impact on hematologic response and toxicity of adding dexamethasone

    Impact on hematologic response and toxicity of adding dexamethasone to carfilzomib in patients with suboptimal hematologic responses (defined as \<VGPR after 4 cycles)

    Time frame: Every 28 days throughout treatment after dexamethasone is added (estimated at 4 months per patient)

  2. Biomarkers of carfilzomib sensitivity

    Evaluate potential biomarkers of carfilzomib sensitivity in baseline purified bone marrow plasma cells, including proteasomal capacity and in vitro sensitivity to proteasome inhibition.

    Time frame: Baseline

  3. Prognostic significance of cycle D1 expression

    To explore the prognostic significance of cyclin D1 expression in purified bone marrow plasma cells in patients with previously treated AL amyloidosis

    Time frame: Baseline

07

Study locations

10 sites
  • City of Hope
    Duarte, California 91010, United States
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Columbia University
    New York, New York 10032, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • Abramson Cancer Center at the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Dec 2016 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2013
First posted
Feb 12, 2013
Start
Feb 2013
Primary completionActual
Dec 2016
CompletionActual
Jul 2017
Last update
Oct 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01789242
Lead sponsor
Criterium, Inc.
Collaborators
Amgen
Responsible party
Sponsor
First posted
Feb 12, 2013
Start date
Feb 2013
Primary completion
Dec 2016
Completion
Jul 2017
Last update
Oct 18, 2017

Study contacts

Adam Cohen, MD
principal investigator · AMyC; Univ of Penn Perelman Center for Advanced Medicine
Brian GM Durie, MD
principal investigator · AMyC
Raymond Comenzo, MD
principal investigator · AMyC, Tufts University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion